News Post 28-06-2021

#SOLVECoV2: 10 Saxony biotech solutions to fight the pandemic

Biotechnology and medical technology companies based in Saxony made a significant contribution to combating the corona pandemic. A digital campaign titled #SOLVECoV2 was launched by Saxon industry association biosaxony e.V. on the 22nd of June, 2021.

The main purpose of this campaign is to acknowledge the effective contribution of the Saxon companies in combating the pandemic, to help the Saxon-based companies attain greater visibility, and to show that Saxony is one of the most dynamic life sciences locations in Europe. In the course of the digital campaign, 10 exemplary Saxon innovations are presented.

These exemplary companies were able to come up with the know-how and develop diverse products in the shortest time possible. Their innovations are being used worldwide for the diagnosis of the COVID-19 virus, for the production of vaccines, or for the ventilation of intensive care patients.
Here is an excerpt of the article about Biotype. The complete campaign can be found at:

Based in Dresden, Biotype GmbH has been producing qPCR tests in support to clinics and large laboratories for the diagnosis of COVID-19

Biotype GmbH has produced and delivered more than 18 million corona tests to date. The Saxon-based company immediately responded to the news from China, and within a very short period, it re-directed its capacities to fight the SARS-CoV-2 pandemic. In fact, in only 14 days from the start of the project, the team was able to deliver the first batch of PCR tests. Biotype has been producing components for a qPCR-based diagnostic test that can be used in laboratories (qPCR -quantitative polymerase chain reaction). The diagnostic test allows fast and highly sensitive detection of the current SARS-CoV-2 virus.

In addition, Biotype also developed its own diagnostic test for SARS-CoV-2 detection on its innovative Modaplex Plattform.

As a full-service provider, Biotype has allocated all its strengths to quickly address the challenges incurred by the pandemic. The company succeeded in addressing these challenges through the investment in necessary technical equipment and materials and through the significant increase in production quantities in a short time frame to accommodate the increased demands. Biotype has created new job opportunities through hiring additional employees, including university students. In addition to contract production, Biotype also secured the distribution rights to supply hospitals and large laboratories with the needed diagnostic tests.